Pump thrombosis

Last updated
Pump thrombosis
Other namesPump-related thrombosis

Pump thrombosis (PT) is considered a specific case of a major device malfunction, and is classified as either suspected or confirmed pump thrombus. Typically, the device is an implanted blood pump such as a Left ventricular assist device. The malfunction is a blockage in the flow of blood anywhere along a vessel (upstream or downstream) and it is mainly due to the bio-incompatible presence of a fairly complex mechanical apparatus. Pump thrombus is dreaded complication of CF LVAD technology [1] that can require repeat surgery to replace the pump or lead to death. [2]

Contents

In suspected pump thrombus, the clinical patient condition or pump parameters suggest thrombus on any of the blood-contacting surfaces of the pump (inflow cannula, pump itself, or outflow graft).Confirmed pump thrombus is done by visual inspection (during device exchange, transplantation, autopsy), irrefutable radiographic evidence, or absence of Doppler inflow or outflow signals.Not all ventricular assist devices (VADs) are fully biocompatible, thus device thrombosis has always been a significant complication. Older generation pulsatile VADs were relatively large and it was practically impossible to thrombose the entire pump and cause hemodynamic consequences.Instead, any thrombus created in the pump could be dislodged, possibly resulting in an embolic stroke. In contrast, the newer continuous flow left ventricular assist devices (CF LVAD) are much smaller and have smaller gaps between the various components of the pump. These characteristics predispose CF LVAD to thrombosis of the entire pump where the clot stays in the device, leading to increased hemolysis and device dysfunction.[ citation needed ]

Thrombosis of CF LVADSs can occur as a result of various factors, [3] which can be divided into three categories: the pump, the patient, and the clinician. Management protocols for VADs are usually institution-dependent and there is a large variability in clinician-related factors. A decrease in anticoagulation thresholds [4] [5] [6] has been postulated to have resulted in an increase in CF LVAD thrombosis. [7] [8]

A complex balance exists between over-anticoagulation and under-anticoagulation, in a patient population where the coagulation system response to the CF LVAD device varies greatly between individuals. Common adverse events precipitated by over-anticoagulation include bleeding problems such as gastrointestinal bleeding and intracranial hemorrhage, while common complications due to under-anticoagulation include hemolysis, pump thrombosis and ischemic/embolic strokes.[ citation needed ]

Unfortunately, robust and individually-tailored anticoagulation therapy protocols do not exist in most institutions, which usually utilize a “one size fits all” approach. One anticoagulation protocol example targets the therapeutic window of coumadin of an International Normalized Ratio (INR) goal of 2-3 and full-dose aspirin for antiplatelet activity. In the complex dynamics of the interaction of patients’ systems, there is no completely safe zone between thrombosis or bleeding, or both.

Definition

Pump thrombosis is defined as a specific case of a major device malfunction. In turn, device malfunction is as defined by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) as a failure of one or more of the components of the mechanical circulatory support systems which either directly causes or could potentially induce a state of inadequate circulatory support (low cardiac output state) or death. A failure that was iatrogenic or recipient-induced will be classified as an Iatrogenic/Recipient-Induced failure.[ citation needed ]

Device failure should be classified according to which component fails as follows:

1. Pump failure (blood containing components of pump and any motor or other pump actuating mechanism that is housed with the blood contacting components). In the special situation of pump thrombosis, thrombus is documented to be present within the device or its conduits that result in or could potentially induce circulatory failure.

2. Non-pump failure (e.g., external pneumatic device unit, electric power supply unit, batteries, controller, interconnect cable, compliance chamber). [9]

Problems

The FDA is aware of serious adverse events associated with LVADs. It has received reports and information from a variety of sources indicating an increase in the rate of pump thrombosis events in patients implanted with LVADs. Information also shows that patients are experiencing pump thrombosis events earlier than observed during the clinical trials conducted to support product approvals in 2008 Bridge To Transplant (BTT) and 2010 Destination Therapy (DT).[ citation needed ]

Two analyses in scientific literature reported the confirmed (after explant) pump thrombosis rate as high as 8.4% of implanted devices at 3 months (Starling et al, 2013) and 6% of implanted devices at 6 months (Kirklin et al, 2014). This is compared to 1.6% of implanted devices at one year during the BTT clinical trial and 3.8% of implanted devices at 2 years during the DT clinical trial. [10]

Cause

The cause for PT are classified as either pump-related, patient-related, or management-related. But of particular concern is the emergence in some reports of HIT syndrome as an etiologic factor in some cases of PT. [11] [12] [13]

Inherent to the technology itself. Examples: Heat generated by pump rotor; Outflow graft kink.

Individual conditions that render patient more likely to have thrombotic complications. Examples: Atrial fibrillation; Infection.

1. Implantation technique. Example: Inflow cannula malposition. 2. Inadequate anticoagulation. Examples: No heparin bridging; subtherapeutic INR. 3. Low pump flow due to low speed setting to manage AI, GIB or assess/induce recovery.

Diagnosis

Criteria should include the presence of hemolysis, presence of heart failure not explained by structural disease, and/or abnormal pump parameters. Imaging and functional studies (ramp) can confirm diagnosis. [14] Elevated lactate dehydrogenase (LDH) levels. [15]

Prevention

The complication itself, its prevention, or its treatment may lead to PT. Prevention of GI bleeding in VAD patients often includes keeping pump speeds lower to potentially minimize the proliferation of AV malformations.

In addition, bleeding, once it occurs, is managed at least temporarily by a halting or decrease in AC. Efforts to decrease the development of AI in LVAD patients include keeping pump speeds on the lower side as well.

Right ventricular dysfunction, particularly in the early postoperative period, is likewise managed with lower pump speeds. Finally, infections and sepsis are known to be associated with a more hypercoagulable state in VAD patients. In the end, the occurrence of any of these complications may thus prove to be a surrogate for a higher risk of PT.

While the issue of biocompatibility is always be at the forefront of critical issues of new pumps, the field of mechanical circulatory support is first focusing on adopting a standardized approach to this therapy so that valid analyses and comparisons can be made. [16]

Management

No standardized protocol exist regarding the management of LVAD pump thrombosis. [17]

No standardized protocol exist regarding therapy of pump thrombosis. [18]

History

Beginning in 2011, centers and collaborative groups began to observe a significant increase in the incidence of pump thrombosis, which led to pump modifications and the appreciation of more strict control of blood pressure and anticoagulation with this pump design. [19]

The unexpected abrupt increase in LVAD thrombosis was accompanied by elevated lactate dehydrogenase (LDH) levels with outcomes of different management strategies in a multi-institutional study.,, [20] [21] [22] Elevation of lactate dehydrogenase during the first month offers an opportunity for early intervention strategies. [23]

Starting in approximately March 2011, the occurrence of confirmed pump thrombosis at 3 months after implantation increased from 2.2% to 8.4% by January 1, 2013.[ citation needed ]

Before March 1, 2011, the median time from implantation to thrombosis was 18.6 months, and from March 2011 onward, it was 2.7 months. The occurrence of elevated LDH levels within 3 months after implantation mirrored that of thrombosis. Thrombosis was presaged by LDH levels that more than doubled, from 540 IU per liter to 1490 IU per liter, within the weeks before diagnosis.

While starting in 2011 device failures due to clots forming inside the pumps appeared to rise dramatically, there is some indication that these failures may now be declining, but data analysis and interpretation are complex.> [24]

Research

Computational fluid dynamics (CFD) is an invaluable tool in the development of VADs, enabling new designs to be tested rapidly and undesirable flow characteristics eliminated in successive versions before prototypes are manufactured. CFD is used for predicting pressure-flow characteristics and efficiency curves, revealing the detailed flow field to help eliminate regions of recirculation or stagnation and for calculating fluid dynamic forces. When combined with models of blood damage CFD has been used for predicting haemolysis and platelet activation by VADs. When combined with shape optimization algorithms it can be used in design optimization. [25]

Related Research Articles

<span class="mw-page-title-main">Venous thrombosis</span> Blood clot (thrombus) that forms within a vein

Venous thrombosis is the blockage of a vein caused by a thrombus. A common form of venous thrombosis is deep vein thrombosis (DVT), when a blood clot forms in the deep veins. If a thrombus breaks off (embolizes) and flows to the lungs to lodge there, it becomes a pulmonary embolism (PE), a blood clot in the lungs. The conditions of DVT only, DVT with PE, and PE only, are all captured by the term venous thromboembolism (VTE).

<span class="mw-page-title-main">Artificial heart</span> Mechanical device which replaces the heart

An artificial heart is an artificial organ device that replaces the heart. Artificial hearts are typically used to bridge the time to heart transplantation, or to permanently replace the heart in the case that a heart transplant is impossible. Although other similar inventions preceded it from the late 1940s, the first artificial heart to be successfully implanted in a human was the Jarvik-7 in 1982, designed by a team including Willem Johan Kolff, William DeVries and Robert Jarvik.

<span class="mw-page-title-main">Cardiopulmonary bypass</span> Technique that temporarily takes over the function of the heart and lungs during surgery

Cardiopulmonary bypass (CPB) is a technique in which a machine temporarily takes over the function of the heart and lungs during cardiac surgery, maintaining the circulation of blood and oxygen to the body. The CPB pump itself is often referred to as a heart-lung machine or "the pump". Cardiopulmonary bypass pumps are operated by perfusionists. CPB is a form of extracorporeal circulation. Extracorporeal membrane oxygenation (ECMO) is generally used for longer-term treatment.

<span class="mw-page-title-main">Extracorporeal membrane oxygenation</span> Technique of providing both cardiac and respiratory support

Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life support (ECLS), is an extracorporeal technique of providing prolonged cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of gas exchange or perfusion to sustain life. The technology for ECMO is largely derived from cardiopulmonary bypass, which provides shorter-term support with arrested native circulation. The device used is a membrane oxygenator, also known as an artificial lung.

<span class="mw-page-title-main">Coronary thrombosis</span> Medical condition

Coronary thrombosis is defined as the formation of a blood clot inside a blood vessel of the heart. This blood clot may then restrict blood flow within the heart, leading to heart tissue damage, or a myocardial infarction, also known as a heart attack.

<span class="mw-page-title-main">Peripartum cardiomyopathy</span> Medical condition

Peripartum cardiomyopathy (PPCM) is a form of dilated cardiomyopathy that is defined as a deterioration in cardiac function presenting typically between the last month of pregnancy and up to six months postpartum. As with other forms of dilated cardiomyopathy, PPCM involves systolic dysfunction of the heart with a decrease of the left ventricular ejection fraction (EF) with associated congestive heart failure and an increased risk of atrial and ventricular arrhythmias, thromboembolism (blockage of a blood vessel by a blood clot), and even sudden cardiac death. In essence, the heart muscle cannot contract forcefully enough to pump adequate amounts of blood for the needs of the body's vital organs.

<span class="mw-page-title-main">Cardiogenic shock</span> Medical emergency resulting from inadequate blood flow due to dysfunction of heart ventricles

Cardiogenic shock is a medical emergency resulting from inadequate blood flow to the body's organs due to the dysfunction of the heart. Signs of inadequate blood flow include low urine production, cool arms and legs, and decreased level of consciousness. People may also have a severely low blood pressure and heart rate.

<span class="mw-page-title-main">O. H. Frazier</span> American physician

O. H. "Bud" Frazier is a heart surgeon and director of cardiovascular surgery research at the Texas Heart Institute (THI), best known for his work in mechanical circulatory support (MCS) of failing hearts using left ventricular assist devices (LVAD) and total artificial hearts (TAH).

Sean Patrick Pinney is an American cardiologist and the Director of both the Advanced Heart Failure and Cardiac Transplant Program and the Pulmonary Hypertension Program at Mount Sinai Medical Center in New York City.

Management of heart failure requires a multimodal approach. It involves a combination of lifestyle modifications, medications, and possibly the use of devices or surgery.

Destination therapy is a therapy that is final rather than being a transitional stage until another therapy—thus, in transportation metaphor, a destination in itself rather than merely a bridge or road to the destination. The term usually refers to ventricular assist devices or mechanical circulatory support to keep the existing heart going, not just until a heart transplant can occur, but for the rest of the patient's life expectancy. It is thus a course of treatment for severe heart failure patients who are not likely candidates for transplant. In contrast, bridge-to-transplant therapy is a way to stay alive long enough, and stay healthy enough, to await transplant while maintaining eligibility for transplant.

Thoratec Corporation is a United States-based company that develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart-failure patients worldwide. It is a global leader in mechanical circulatory support devices, particularly in ventricular assist devices (VADs).

Impella is a family of medical devices used for temporary ventricular support in patients with depressed heart function. Some versions of the device can provide left heart support during other forms of mechanical circulatory support including ECMO and Centrimag.

William F. Bernhard was an American cardiovascular surgeon, Emeritus Professor of Surgery at Harvard Medical School, and cardiovascular surgical pioneer.

Sharon Ann Hunt is a cardiology professor and Director of the Post Heart Transplant Programme in Palo Alto, California and is affiliated with Stanford University Medical Center, professionally known for her work in the care of patients after heart transplantation.

ReliantHeart, Inc. is a privately held American company headquartered in Houston, Texas that designs, manufactures, and provides remote monitoring capabilities for its left ventricular assist devices which are used to assist circulation for failing hearts.

Berlin Heart GmbH is a German company that develops, produces and markets ventricular assist devices (VADs). The devices mechanically support the hearts of patients with end-stage heart failure. Berlin Heart's products include the implantable INCOR VAD and the paracorporeal EXCOR VAD. To date, Berlin Heart produces the only device of its kind available for babies and children with severe heart failure.

Bridge therapy is therapy intended, in transportation metaphor, to serve as a figurative bridge to another stage of therapy or health, carrying a patient past a challenging period of some kind. There are various types of bridge therapy, such as bridge to transplant, bridge to candidacy, bridge to decision, bridge to recovery, and anticoagulation bridge. Bridge therapy exists in contrast to destination therapy, which is the figurative destination rather than a bridge to something else.

Eric A. Rose is an American cardiothoracic surgeon, scientist, entrepreneur and professor and Chairman of the Department of Population Health Science & Policy, and Associate Director for Clinical Outcomes at Mount Sinai Heart. He is best known for performing the first successful paediatric heart transplant, in 1984 while at NewYork–Presbyterian Hospital (NYP).

References

  1. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2016-02-22. Retrieved 2016-02-05.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ↑ "Serious Adverse Events with Implantable Left Ventricular Assist Devices (LVADs): FDA Safety Communication". Food and Drug Administration . Archived from the original on 2017-07-22. Retrieved 2019-12-16.
  3. ↑ Uriel, N; Han, J; Morrison, KA; et al. (2014). "Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon". J Heart Lung Transplant. 33 (1): 51–9. doi: 10.1016/j.healun.2013.10.005 . PMID   24290832.
  4. ↑ Slaughter, MS; Naka, Y; John, R; et al. (2010). "Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy". J Heart Lung Transplant. 29 (6): 616–24. doi: 10.1016/j.healun.2010.02.003 . PMID   20400335.
  5. ↑ Slater JP, Rose EA, Levin HR, et al. Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices. Ann Thorac Surg 1996;62:1321-7; discussion 1328.
  6. ↑ Netuka, I; Litzler, PY; Berchtold-Herz, M; et al. (2014). "Minimal adverse events in HeartMate II patients with no antiplatelet therapy: preliminary results from the European TRACE study". J Heart Lung Transpl. 33 (4): S11. doi:10.1016/j.healun.2014.01.055.
  7. ↑ Kirklin, JK; Naftel, DC; Kormos, RL; et al. (2014). "Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device". J Heart Lung Transplant. 33 (1): 12–22. doi: 10.1016/j.healun.2013.11.001 . PMID   24418730.
  8. ↑ Starling, RC; Moazami, N; Silvestry, SC; et al. (2014). "Unexpected abrupt increase in left ventricular assist device thrombosis". N Engl J Med. 370 (1): 33–40. doi: 10.1056/nejmoa1313385 . PMID   24283197. S2CID   54522781.
  9. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2016-02-22. Retrieved 2016-02-05.{{cite web}}: CS1 maint: archived copy as title (link)
  10. ↑ "Serious Adverse Events with Implantable Left Ventricular Assist Devices (LVADs): FDA Safety Communication". Food and Drug Administration . Archived from the original on 2017-07-22. Retrieved 2019-12-16.
  11. ↑ Wu, L; Weng, YG; Dong, NG; et al. (2013). "Outcomes of HeartWare Ventricular Assist System support in 141 patients: a single-centre experience". Eur J Cardiothorac Surg. 44 (1): 139–45. doi: 10.1093/ejcts/ezs263 . PMID   22858453.
  12. ↑ Warkentin, TE; Greinacher, A; Koster, A (2009). "Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required?". Ann Thorac Surg. 87 (5): 1633–40. doi:10.1016/j.athoracsur.2008.10.060. PMID   19379937.
  13. ↑ Pappalardo, F; Scandroglio, AM; Potapov, E; et al. (2012). "Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices". Minerva Anestesiol. 78 (3): 330–5. PMID   22357371.
  14. ↑ Management of Pump Thrombosis in Patients With Left Ventricular Assist Devices John M. Stulak; Shashank Sharma; Simon Maltais.
  15. ↑ Starling, RC; Moazami, N; Silvestry, SC; et al. (2014). "Unexpected abrupt increase in left ventricular assist device thrombosis". N Engl J Med. 370 (1): 33–40. doi: 10.1056/nejmoa1313385 . PMID   24283197. S2CID   54522781.
  16. ↑ Blitz, A (2014). "Pump thrombosis-A riddle wrapped in a mystery inside an enigma". Ann Cardiothorac Surg. 3 (5): 450–71. doi:10.3978/j.issn.2225-319X.2014.09.10. PMC   4229470 . PMID   25452905.
  17. ↑ "Management of Pump Thrombosis in Patients with LVADs".
  18. ↑ "Management of Pump Thrombosis in Patients with LVADs".
  19. ↑ Management of Pump Thrombosis in Patients With Left Ventricular Assist Devices John M. Stulak; Shashank Sharma; Simon Maltais.
  20. ↑ Starling, Randall C.; Moazami, Nader; Silvestry, Scott C.; Ewald, Gregory; Rogers, Joseph G.; Milano, Carmelo A.; Rame, J. Eduardo; Acker, Michael A.; Blackstone, Eugene H.; Ehrlinger, John; Thuita, Lucy; Mountis, Maria M.; Soltesz, Edward G.; Lytle, Bruce W.; Smedira, Nicholas G. (2014). "Unexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis". New England Journal of Medicine. 370 (1): 33–40. doi: 10.1056/NEJMoa1313385 . PMID   24283197. S2CID   54522781.
  21. ↑ Sherman, Toni Clarke (16 April 2011). "HeartWare device had 9.2 percent thrombosis rate in trial". Reuters.
  22. ↑ "Are Blood Clots in Patients with Heart-Assist Pumps Decreasing or on the Rise in 2015?".
  23. ↑ Kirklin, James K.; Naftel, David C.; Pagani, Francis D.; Kormos, Robert L.; Myers, Susan; Acker, Michael A.; Rogers, Joseph; Slaughter, Mark S.; Stevenson, Lynne W. (1 December 2015). "Pump thrombosis in the Thoratec HeartMate II device: An update analysis of the INTERMACS Registry" (PDF). The Journal of Heart and Lung Transplantation. 34 (12): 1515–1526. doi:10.1016/j.healun.2015.10.024. PMID   26681121 . Retrieved 1 March 2023.
  24. ↑ "Are Blood Clots in Patients with Heart-Assist Pumps Decreasing or on the Rise in 2015?" (PDF). Elsevier Health Sciences. 2 December 2015. Retrieved 1 March 2023.
  25. ↑ Fraser, KH; Taskin, ME; Griffith, BP; Wu, ZJ (2011). "The use of computational fluid dynamics in the development of ventricular assist devices". Med Eng Phys. 33 (3): 263–80. doi:10.1016/j.medengphy.2010.10.014. PMC   3053072 . PMID   21075669.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.